Montelukastum Unimark (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukastum Unimark, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children, working by blocking cysteinyl leukotriene receptors and reducing airway inflammation.

GNH USA supplies Montelukastum Unimark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Montelukastum Unimark, a leukotriene receptor antagonist, is indicated for conditions mediated by cysteinyl leukotrienes. - Asthma: Improves control of persistent asthma by reducing airway inflammation and preventing bronchoconstriction. - Allergic rhinitis: Relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: Prevents narrowing of the airways that can occur during or after physical exertion.

Montelukastum Unimark may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Upper respiratory tract infection: nasopharyngitis‑like symptoms such as sore throat and runny nose. - Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, or angioedema that may require medical attention. - Neuropsychiatric events: agitation, anxiety, depression, or suicidal thoughts reported in rare cases. - Hepatotoxicity: elevated liver enzymes or clinically apparent hepatitis, requiring monitoring.

When prescribing Montelukastum Unimark, clinicians should consider several precautionary measures to ensure safe use. - Contraindication: known hypersensitivity to montelukast or any tablet excipients. - Caution in asthma: not a substitute for rescue bronchodilators; maintain short‑acting inhaler. - Pregnancy: limited data; use only if potential benefit justifies potential risk. - Breastfeeding: montelukast excreted in milk; weigh benefits against infant exposure. - Drug interactions: review concomitant medications that may affect leukotriene pathways. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Montelukast may interact with other medicines; awareness of major and moderate interactions helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital, carbamazepine, rifampin: strong enzyme inducers that can lower montelukast plasma concentrations. - Ritonavir: may increase montelukast levels, raising risk of adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Theophylline: additive bronchodilator effects; observe for increased side effects. - Zafirlukast: concurrent leukotriene receptor antagonists may increase risk of liver enzyme abnormalities.